Healthcare Industry News: Blueprint Medicines
News Release - June 29, 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business OfficerBURLINGAME, Calif., June 29, 2016 -- (Healthcare Sales & Marketing Network) -- Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced it has named former Roche/Genentech Vice President, Global Head of Roche Oncology Business Development, Jason, V. Coloma, Ph.D., to the newly created post of Senior Vice President and Chief Business Officer.
“Jason’s experience across large pharma and development stage biotech, particularly in oncology, means he brings to Corvus a deep understanding of the opportunities and strategy necessary to build a successful portfolio of cancer products,” said Richard A. Miller, M.D., an oncologist and co-founder, president and chief executive officer of Corvus. “Dr. Coloma is ideally suited to help us commercialize our current product candidates and to in-license or acquire additional product opportunities.”
“This is an exciting time to be working in the field of immuno-oncology,” said Dr. Coloma. “I am particularly pleased to become part of the Corvus team of accomplished and talented clinical and scientific experts who are working on cutting edge approaches to immuno-oncology and helping deliver innovative therapies to patients.”
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444 is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with TECENTRIQ™ (atezolizumab), Genentech's investigational cancer immunotherapy. TECENTRIQ™ is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit www.corvuspharma.com.
Source: Corvus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.